US Bancorp DE Reduces Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

US Bancorp DE cut its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 46.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 945 shares of the company’s stock after selling 818 shares during the period. US Bancorp DE’s holdings in Krystal Biotech were worth $172,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. EFG Asset Management North America Corp. boosted its position in Krystal Biotech by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock valued at $2,308,000 after acquiring an additional 60 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Krystal Biotech by 160.3% during the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after purchasing an additional 93 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in Krystal Biotech by 11.1% in the second quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock worth $173,000 after purchasing an additional 94 shares during the period. Arizona State Retirement System grew its stake in Krystal Biotech by 2.1% in the second quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock worth $945,000 after purchasing an additional 108 shares during the period. Finally, Fiera Capital Corp raised its holdings in Krystal Biotech by 0.8% in the second quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock worth $2,976,000 after purchasing an additional 130 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Down 3.7 %

Shares of Krystal Biotech stock opened at $177.39 on Friday. The company has a market capitalization of $5.10 billion, a price-to-earnings ratio of 104.08 and a beta of 0.82. The stock’s 50-day simple moving average is $181.27 and its 200-day simple moving average is $181.38. Krystal Biotech, Inc. has a 52 week low of $96.73 and a 52 week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm’s revenue for the quarter was up 879.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.67) EPS. On average, equities analysts expect that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Analyst Ratings Changes

KRYS has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a report on Tuesday, November 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Evercore ISI lifted their target price on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a report on Monday, August 12th. Stifel Nicolaus boosted their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Finally, Citigroup raised their price objective on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Krystal Biotech has a consensus rating of “Buy” and an average price target of $197.00.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. This represents a 1.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 14.10% of the stock is currently owned by corporate insiders.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).